Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PEPG 
PepGen Ltd (PEPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: PEPG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.83
1 Year Target Price $6.83
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.4% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.54M USD | Price to earnings Ratio - | 1Y Target Price 6.83 |
Price to earnings Ratio - | 1Y Target Price 6.83 | ||
Volume (30-day avg) 5 | Beta 1.17 | 52 Weeks Range 0.88 - 10.05 | Updated Date 09/14/2025 |
52 Weeks Range 0.88 - 10.05 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.44% | Return on Equity (TTM) -85.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -8245409 | Price to Sales(TTM) - |
Enterprise Value -8245409 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.11 | Shares Outstanding 32799700 | Shares Floating 14526998 |
Shares Outstanding 32799700 | Shares Floating 14526998 | ||
Percent Insiders 0.27 | Percent Institutions 89.49 |
Upturn AI SWOT
PepGen Ltd
Company Overview
History and Background
PepGen Ltd. is a biotechnology company focused on developing next-generation oligonucleotide therapeutics for neuromuscular and other diseases. Founded in 2018, PepGen has advanced its Enhanced Delivery Oligonucleotide (EDO) platform to address previously undruggable targets. The company has rapidly moved into clinical trials.
Core Business Areas
- Neuromuscular Disease Therapeutics: Development of oligonucleotide therapeutics for Duchenne muscular dystrophy (DMD) and other neuromuscular disorders.
Leadership and Structure
James McArthur, Ph.D., is the President and CEO. The company operates with a functional structure typical of biotech companies, with departments focused on R&D, clinical development, and commercial strategy.
Top Products and Market Share
Key Offerings
- Pgn-EDO51: Pgn-EDO51 is a lead candidate for Duchenne Muscular Dystrophy (DMD) patients amenable to exon 51 skipping. It is currently in clinical trials. The market size for DMD therapies is significant, with competitors including Sarepta Therapeutics (SRPT). Market share is not yet established as the product is in clinical development.
Market Dynamics
Industry Overview
The oligonucleotide therapeutics market is experiencing rapid growth, driven by advancements in delivery technologies and a growing understanding of disease mechanisms. Key players include pharmaceutical giants and specialized biotech companies.
Positioning
PepGen positions itself as a leader in next-generation oligonucleotide delivery, leveraging its EDO platform to target diseases with high unmet need. Its competitive advantage lies in enhanced cellular uptake and target engagement.
Total Addressable Market (TAM)
The TAM for DMD therapies is estimated to be in the billions of dollars annually. PepGen is positioned to capture a significant share of this market if Pgn-EDO51 proves successful in clinical trials. Other target diseases in PepGen's pipeline increase TAM.
Upturn SWOT Analysis
Strengths
- Proprietary EDO platform for enhanced oligonucleotide delivery
- Strong intellectual property position
- Experienced management team
- Focus on high unmet need diseases
Weaknesses
- Limited clinical data to date
- Reliance on a single technology platform
- High cash burn rate
- Competition from established players
Opportunities
- Expansion of EDO platform to new disease targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results for Pgn-EDO51
- Advancements in genetic therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other oligonucleotide therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- SRPT
- BMY
- AVXS
Competitive Landscape
PepGen's competitive advantage lies in its EDO platform, which offers enhanced oligonucleotide delivery compared to some existing therapies. However, the company faces competition from established players with approved products and larger resources.
Growth Trajectory and Initiatives
Historical Growth: PepGen's historical growth is characterized by the advancement of its EDO platform and the initiation of clinical trials.
Future Projections: Future growth is dependent on the success of Pgn-EDO51 and other pipeline programs. Analyst estimates vary widely, reflecting the inherent uncertainty of clinical-stage biotech companies.
Recent Initiatives: Recent initiatives include the initiation of Phase 1/2 clinical trials for Pgn-EDO51 and exploration of new disease targets for the EDO platform.
Summary
PepGen is a clinical-stage biotech company with a promising technology platform for oligonucleotide therapeutics. While the company shows a lot of promise with its technology, it's financial health depends on the progress of clinical trials. Competition from established players remains a significant challenge. Success in clinical trials is the key to unlocking significant value for shareholders. PepGen's enhanced delivery system also adds a differentiator to increase valuation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PepGen Ltd
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2022-05-06 | President, CEO, Treasurer, Secretary & Director Dr. James G. McArthur Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 62 | Website https://pepgen.com |
Full time employees 62 | Website https://pepgen.com | ||
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.